Differential physiological effects of a low dose and high doses of venlafaxine in major depression

International Journal of Neuropsychopharmacology

Volumn 10, Issue 1, 2007, Pages 51-61

  Debonnel, Guy ^a   Saint André, Élise ^a   Hébert, Chantal ^a,b   De Montigny, Claude ^a   Lavoie, Normand ^a   Blier, Pierre ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Norepinephrine reuptake; Serotonin reuptake; Tyramine

Indexed keywords

CHLORAL HYDRATE; CLONAZEPAM; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TYRAMINE; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; ATTENUATION; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; SYSTOLIC BLOOD PRESSURE; TREMOR; VASODILATATION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; BLOOD PRESSURE; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TYRAMINE;

EID: 33846277237     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006413     Document Type: Article

References (45)

1. Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM (1999). Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. British Journal of Clinical Pharmacology 48, 345-354.
2. APA (1987). Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association.
3. Bitsios P, Szabadi E, Bradshaw CM (1999). Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berlin) 143, 286-292.
4. Blier P, Saint-André É, Hébert C, de Montigny C, Lavoie N, Debonnel C (2006). Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. International Journal of Neuropsychopharmacology. doi: 10.1017/S1461145705006395.
5. Bowsher DJ, Rowe H, Farid NA, Tenbarge JB, Lemberger L (1988). Pressor responses to tyramine and norepinephrine after subchronic administration of fluoxetine to man. Life Sciences 42, 2569-2575.
6. Celada P, Martin F, Artigas F (1994). Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sciences 55, 1237-1243.
7. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ (2003). Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 28, 1685-1693.
8. Clerc GE, Ruimy P, Verdeau-Palles J (1994). A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. International Clinical Psychopharmacology 9, 139-143.
9. Dajas F, Lista A, Barbeito L (1984). High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163). Acta Psychiatrica Scandinavica 70, 432-437.
10. de Montigny C, Silverstone DH, Debonnel G, Blier P, Bakish D (1999). Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. Journal of Clinical Psychopharmacology 19, 401-406.
11. Demet EM, Halaris AE, Bhatarakamol S (1978). Indoleamine compartmentation in human blood. Clinica Chimica Acta 89, 285-292.
12. Feinstein MB, Fraser C (1975). Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP. Journal of General Physiology 66, 561-581.
13. Ghose K (1984). Tyramine pressor test: implications and limitations. Methods and Findings in Experimental and Clinical Pharmacology 6, 455-464.
14. Ghose K, Turner P (1975). Intravenous tyramine pressor response in depression. Lancet 1, 1317-1318.
15. Gobbi G, Slater S, Boucher N, Debonnel G, Blier P (2003). Neurochemical and psychotropic effects of bupropion in healthy male subjects. Journal of Clinical Psychopharmacology 23, 233-239.
16. Goldberg HL, Finnerty R (1988). An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients. Psychopharmacology Bulletin 24, 198-199.
17. Gould GG, Altamirano AV, Javours MA, Frazer A (2005). A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biological Psychiatry Published online: 1 Sept. 2005. Pubmed ID: 16140280.
18. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G (1995). Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry 56, 450-458.
19. Guy W (1976). Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, Rockville, MD.
20. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
21. Harvey AT, Rudolph RL, Preskorn SH (2000). Evidence of the dual mechanisms of action of venlafaxine. Archives of General Psychiatry 57, 503-509.
22. Hassan SM, Wainscott G, Turner P (1985). A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test. British Journal of Clinical Pharmacology 19, 705-706.
23. Hassan SM, Wainscott G, Turner P (1989). Paroxetine: lack of effect on the tyramine pressor response in man. Acta Psychiatrica Scandinavica (Supplementum) 350, 49.
24. Hoffman BB, Lefkowitz RJ (1990) Catecholamines and sympathomimetic drugs. In: Gilman AG, Rall TW, Nies AS, Taylor P (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, Eighth Edition (pp. 187-220). New York: Macmillan Publishing Co.
25. Houston DS, Vanhoutte PM (1986). Serotonin and the vascular system. Role in health and disease, and implications for therapy. Drugs 31, 149-163.
26. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST (1996). Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 16, 915-923.
27. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, Ordway GA (1997). Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. Journal of Neuroscience 17, 8451-8458.
28. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. American Journal of Psychiatry 157, 1445-1452.
29. Melichar JK, Haida A, Rhodes C, Reynolds AH, Nutt DJ, Malizia AL (2001). Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. Journal of Psychopharmacology 15, 9-12.
30. Montgomery S, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
31. Muth E, Moyer J, Haskins J, Andree T, Husbands G (1991). Biochemical, neurophysiological, and behavioral effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research 23, 191-199.
32. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994). Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology 14, 419-423.
33. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD (1999). Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Research 87, 1-5.
34. Pletscher A, Da Prada M, Pranzer JP (1968). The action of calcium and thrombin on isolated 5-hydroxytryptamine organelles of blood platelets. Experientia 24, 1202-1203.
35. Poirier MF, Boyer P (1999). Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry 175, 12-16.
36. Quitkin FM, Stewart JW, McGrath PJ (2001). Gender differences in treatment response [Letter]. American Journal of Psychiatry 158, 1531-1532.
37. Schweizer E, Clary C, Weise C, Rickels K (1988). An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant. Psychopharmacology Bulletin 24, 195-197.
38. Schweizer E, Weise C, Clary C, Fox I, Rickels K (1991). Placebo-controlled trial of venlafaxine for the treatment of major depression. Journal of Clinical Psychopharmacology 11, 233-236.
39. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D (2000). Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. New England Journal of Medicine 342, 541-549.
40. Slater S, Gobbi G, Boucher N, Debonnel C, Blier P (2000). Effects of reboxetine on the norepinephrine reuptake processes in healthy male subjects. New Clinical Drug Evaluation Unit 40, 208.
41. Spitzer RL, Williams JB (1988). Revised diagnostic criteria and a new structured interview for diagnosing anxiety disorders. Journal of Psychiatric Research 22 (Suppl. 1), 55-85.
42. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178, 234-241.
43. Turcotte JE, Debonnel G, de Montigny C, Hébert C, Blier P (2001). Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24, 511-521.
44. Young AH (2001). Gender differences in treatment response to antidepressants. British Journal of Psychiatry 179, 561.
45. Zerbe RL, Rowe H, Enas GG, Wong D, Farid N, Lemberger L (1985). Clinical pharmacology of tomoxetine, a potential antidepressant. Journal of Pharmacology and Experimental Therapeutics 232, 139-143.